AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8112803
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg zinc sulphate (elemental Zn 45 mg) orally/day
Trial: 2461017
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (Logiparin) 35 XaI mu/kg b.w. once daily for 7 days
Trial: 31564231
Drug: 0.40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.40 mg/kg tenecteplase (max 40 mg)
Trial: 31564231
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg tenecteplase (max 25 mg)
Trial: 23916618
Drug: Mediolateral (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediolateral (ML) translations of the walking surface
Trial: 16989200
Drug: Local cutaneous
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local cutaneous alpha therapy with radon applicator (7.4 Bq/l, 90 minutes)
Trial: 8117358
Drug: 32 g
RxNorm normalized name: PEG-32 Glyceryl Laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 g sugar‐beet fibre/d
Trial: 3494725
Drug: Nimorazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimorazole (2 g single dose)
Trial: 27635617
Drug: Pantogam syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantogam syrup 10% (hopantenic acid)
Trial: 20579955
Drug: Betamethasone administered
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone administered in a randomized controlled trial of weekly antenatal corticosteroids (ACS)
Trial: 12889565
Drug: Percutaneous acetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous acetic acid injection (PAI) using 50% acetic acid
Trial: 12889565
Drug: Percutaneous ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous ethanol injection (PEI) using pure ethanol
Trial: 10967901
Drug: Inspiratory resistive
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory resistive load (10 cmH2O/L/sec) during quiet breathing
Trial: 9234616
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with ciprofloxacin (CPFX) and clarithromycin (CAM), 600 mg/day for 14 days
Trial: 9234616
Drug: Single therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single therapy with ciprofloxacin (CPFX), 600 mg/day for 14 days
Trial: 28007405
Drug: Ephedrine 50
RxNorm normalized name: Ephedrine 50 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 50 mg daily in 2 doses
Trial: 25999694
Drug: SYP‐1018 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYP‐1018 (200 mg)
Trial: 25999694
Drug: Vfend(®) (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vfend(®) (200 mg)
Trial: 7935028
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose hormone replacement (0.3 mg/day equine estrogen and 2.5 mg/day medroxyprogesterone)
Trial: 7935028
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose hormone replacement (0.625 mg/day equine estrogen, days 1‐25, and 5 mg/day medroxyprogesterone, days 16‐25)
Trial: 3284690
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (prazosin 2 mg b.i.d. and verapamil 160 mg b.i.d.)
Trial: 3284690
Drug: Single drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single drug treatment (prazosin or verapamil)
Trial: 29611086
Drug: Resveratrol (RSV)
DrugBank: Resveratrol (DB02709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (RSV) 1g daily for 3 months with conventional treatment
Trial: 29611086
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with regular treatment only
Trial: 21934625
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg per day
Trial: 11122840
Drug: Standard and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard and high-dose chemotherapy
Trial: 7617628
Drug: Immunochemotherapy (Tactivin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunochemotherapy (Tactivin + antibacterial drugs)
Trial: 7617628
Drug: Antibacterial drugs
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial drugs alone (Control)
Trial: 2929485
Drug: Animal protein
RxNorm normalized name: Animal protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal protein (AP) diet with increasing vitamin B‐6 intake (0.5, 1.0, 1.5, and 2.0 mg/d) for 14‐21 d
Trial: 2929485
Drug: Plant protein
RxNorm normalized name: Kindersprout Plant Protein Chocolate Shake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant protein (PP) diet with increasing vitamin B‐6 intake (0.5, 1.0, 1.5, and 2.0 mg/d) for 14‐21 d
Trial: 323074
Drug: Lowest dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest dose of norgestrel-ethinyl estradiol (20 microng estrogen, 100 microng progestogen)
Trial: 323074
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of norgestrel-ethinyl estradiol (20 microng estrogen, increased progestogen in 100-microng increments)
Trial: 323074
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of norgestrel-ethinyl estradiol
Trial: 31047803
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan at recommended doses for expansion (5.4 mg/kg or 6.4 mg/kg) administered intravenously once every 3 weeks.
Trial: 31047803
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan at recommended doses for expansion (5.4 mg/kg or 6.4 mg/kg).
Trial: 27364549
Drug: Carvedilol 10mg
RxNorm normalized name: Carvedilol 10mg Oral capsule, extended release
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol 10mg (dose-escalation)
Trial: 27364549
Drug: Carvedilol 20mg
RxNorm normalized name: Carvedilol 20mg Oral capsule, extended release
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol 20mg (dose-escalation)
Trial: 21700688
Drug: Oxygen inhalation
RxNorm normalized name: oxygen INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen inhalation in CMS patients
Trial: 21700688
Drug: Oxygen inhalation
RxNorm normalized name: oxygen INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen inhalation in hypoxemic control subjects
Trial: 21700688
Drug: Oxygen inhalation
RxNorm normalized name: oxygen INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen inhalation in normoxemic control subjects
Trial: 21058471
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy group (acupuncture and mild moxibustion)
Trial: 16338255
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg loading dose, then 75 mg/d) in addition to aspirin for up to 1 year
Trial: 16338255
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in addition to aspirin for up to 1 year
Trial: 11888520
Drug: L-arginine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (30 g for 1 h)
Trial: 9489273
Drug: Repeated imaginal
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated imaginal reliving of trauma during exposure therapy
Trial: 8919895
Drug: PCINA (0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCINA (0.025 mg fentanyl over 6 min)
Trial: 8919895
Drug: i.v.‐PCA (0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v.‐PCA (0.025 mg fentanyl bolus, lockout interval 6 min)
Trial: 1717669
Drug: Rhenium-186(Sn)HEDP, single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhenium-186(Sn)HEDP, single intravenous administration of 30-35 mCi (1110-1295 MBq)
Trial: 7118361
Drug: dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dietary treatment
Trial: 19786658
Drug: Lapatinib (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (1,500 mg orally) plus letrozole (2.5 mg orally)
Trial: 15550024
Drug: Aspirin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (75 mg day(-1))
Trial: 15550024
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg day(-1))
Trial: 11501686
Drug: Adapted preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted preventive intervention for families with parental depression; details on dosage and duration not available.
Trial: 1626493
Drug: Digitalis (digoxin),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digitalis (digoxin), specific dosage and duration not mentioned
Trial: 10405943
Drug: Etidronate therapy
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etidronate therapy (400 mg for 14 days followed by 76 days of calcium carbonate 500 mg, repeated every 3 months)
Trial: 10405943
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (500 to 1000 mg daily)
Trial: 1877455
Drug: Cronassial (mixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cronassial (mixed gangliosides), 40 mg daily intramuscular injection for 4 or 8 weeks
Trial: 3906461
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 3-mg dose
Trial: 3906461
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 5-mg dose
Trial: 29924746
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training using traditional equipment and low-dose testosterone supplementation (ExT)
Trial: 25092781
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) with standard chemotherapy (3 mg/m2/dose, administered once in induction course 1 and once in intensification course 2)
Trial: 25092781
Drug: Standard five-course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard five-course chemotherapy alone
Trial: 25092781
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) with standard chemotherapy
Trial: 18699936
Drug: IVX-0142 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVX-0142 (80 mg)
Trial: 16527229
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment according to the CAPT protocol
Trial: 12953133
Drug: RIST (cladribine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIST (cladribine 0.11 mg/kg/day for 6 days, busulfan 4 mg/kg/day for 2 days, rabbit anti-thymocyte globulin 2.5 mg/kg/day for 2-4 days)
Trial: 10761956
Drug: Self-selected aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-selected aspirin use for at least 180 days/year
Trial: 10761956
Drug: Self-selected aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-selected aspirin use for 0 to 13 days/year
Trial: 8622072
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further regional treatment
Trial: 6386275
Drug: Clonidine 0.3
RxNorm normalized name: CLONIDINE 0.3MG/24HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.3 mg daily
Trial: 6386275
Drug: Guanfacine 3
RxNorm normalized name: guanfacine 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine 3 mg daily
Trial: 19851298
Drug: Oral L-citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral L-citrulline (6 g/day)
Trial: 10482210
Drug: Glucose (dextrose),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (dextrose), 60 g/d
Trial: 8845475
Drug: Intramuscular granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular granisetron
Trial: 1964663
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMW heparin) administered subcutaneously at a dose of 2 X 150 anti‐Xa units/kg body weight, n = 24
Trial: 1964663
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin administered intravenously by continuous infusion at a dose of 450 anti‐Xa units/kg body weight daily for 10 days, n = 26
Trial: 540524
Drug: Amoxapine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxapine (25 mg 3-times daily for 4 weeks)
Trial: 540524
Drug: Imipramine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (25 mg 3-times daily for 4 weeks)
Trial: 12955426
Drug: Tirofiban therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban therapy in addition to aspirin and heparin therapy
Trial: 10871828
Drug: Interferon-beta-1b (Betaferon)
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-beta-1b (Betaferon) 8 MIU subcutaneous every other day
Trial: 10871828
Drug: Interferon-beta-1a (Rebif)
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-beta-1a (Rebif) 6 MIU subcutaneous once a week
Trial: 9378843
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam 0.25 mg/kg
Trial: 8402492
Drug: RG 12915
RxNorm normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG 12915 at 0.25 mg/kg
Trial: 8402492
Drug: RG 12915
RxNorm normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG 12915 at 0.50 mg/kg
Trial: 8402492
Drug: RG 12915
RxNorm normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG 12915 at 1.0 mg/kg
Trial: 8402492
Drug: RG 12915
RxNorm normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG 12915 at 2.0 mg/kg
Trial: 29024323
Drug: Oat bran
RxNorm normalized name: Oat bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat bran (60 g)
Trial: 27302238
Drug: Intra-arterial treatment
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial treatment plus usual care
Trial: 18427536
Drug: Halidor preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halidor preparation (100 mg, 3 times daily)
Trial: 11331627
Drug: Low-dose exogenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose exogenous FSH (75 IU/day) started on cycle day 3
Trial: 11331627
Drug: Low-dose exogenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose exogenous FSH (75 IU/day) started on cycle day 5
Trial: 11331627
Drug: Low-dose exogenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose exogenous FSH (75 IU/day) started on cycle day 7
Trial: 11331627
Drug: Low-dose exogenous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose exogenous FSH (75 IU/day) for all groups
Trial: 7515706
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg of magnesium sulfate intravenously before cardiopulmonary bypass (CPB)
Trial: 7515706
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg of magnesium soon after CPB
Trial: 7515706
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg of magnesium before and after CPB
Trial: 31318225
Drug: Motivational enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational enhancement cognitive-behavioral treatment (MET-CBT)
Trial: 27552564
Drug: (-)-epicatechin (EPI)
RxNorm normalized name: epicatechin
DrugBank: Epicatechin (DB12039)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (-)-epicatechin (EPI) at a total daily dose of 100mg
Trial: 14524058
Drug: Antithrombotic treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic treatments (various types).
Trial: 1569294
Drug: Methionyl growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionyl growth hormone (met‐GH) infusion (160 ng/kg/min lasting 180 min)
Trial: 1569294
Drug: Acipimox sustained
RxNorm normalized name: acipimox
DrugBank: Acipimox (DB09055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox sustained release (ACX-SR) administered at 21:30 h and 09:30 h
Trial: 2866257
Drug: Astemizole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole (10 mg t.i.d. on day 1, 10 mg b.i.d. on day 2, 10 mg o.d. for the remainder of the study)
Trial: 31634003
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of Hyaluronic Acid (HA) 1 week before the marathon
Trial: 24828079
Drug: Citalopram (antidepressant,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (antidepressant, selective serotonin reuptake inhibitor)
Trial: 22723318
Drug: AZD6370 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6370 (300 mg)
Trial: 22723318
Drug: AZD1656 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1656 (80 mg) plus insulin (1 mU/kg · min)
Trial: 22723318
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (0.8 mU/kg · min)
Trial: 22723318
Drug: Insulin alone
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin alone (1 mU/kg · min)
Trial: 15380907
Drug: 250 kcal,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 kcal, 20 g protein supplement
Trial: 15380907
Drug: 250 kcal,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 kcal, 3.5 g protein supplement
Trial: 11472706
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg daily for 12 weeks
Trial: 11472706
Drug: Niacin 3,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin 3,000 mg daily for 12 weeks
Trial: 7851059
Drug: Complete bed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete bed rest for 10 hours after ingestion of the maintenance dose of digoxin
Trial: 3132910
Drug: Two-day cathartic/enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-day cathartic/enema preparation with oral administration of erythromycin and neomycin
Trial: 3132910
Drug: Orthograde lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthograde lavage preparation with oral administration of metronidazole and neomycin
Trial: 29529614
Drug: preopPTEd (one‐on‐one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: preopPTEd (one‐on‐one preoperative physical therapy education session and access to a web‐based microsite)
Trial: 24158878
Drug: Carbetocin 20-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin 20-100 μg iv
Trial: 18520295
Drug: Vandetinib (ZD6474)
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vandetinib (ZD6474) at a dose of up to 300 mg once daily